Community sites vs academic centers: what sponsors should actually compare

Site selection debates usually get framed as prestige versus speed: the academic center with the famous department chair, or the community site that activates while the university is still routing the contract. The framing is lazy, so here is the comparison that actually matters.

Where academic centers genuinely win

Complex inpatient protocols. First-in-human work needing specialized units. Ultra-rare diseases where the national referral center holds the only real patient pool. Studies where a key opinion leader's involvement shapes the science itself. If your protocol needs those things, pay the timeline tax; it is worth it.

Where the timeline tax gets absurd

For the large middle of clinical research, common and moderately complex outpatient studies, the numbers are hard to defend. Median activation across 61 academic cancer centers runs 167 days. Industry-sponsored trials at a university site median 69 days. Meanwhile 80% of independent investigative sites activate within 60 days, and embedded networks like ours compress that further because contracting, regulatory, and feasibility run through one central team instead of per-department committees.

The enrollment story is similar. Academic centers see referred patients, often after the treatment decisions your protocol cares about were already made elsewhere. Community specialists see the disease at the point of first decision, in volume: the moderate psoriasis patient choosing a next therapy, the uncontrolled asthmatic, the gout flare. That is why the same protocol can crawl at a prestigious center and finish early in a strip-mall dermatology office nobody has heard of.

The comparison sponsors should run

Not prestige versus speed but: where does my eligible patient actually receive care at the decision moment my protocol targets? For a large share of protocols, the honest answer is community practices, and diversity follows the same logic, since community sites reflect their communities without a recruitment campaign.

Our suggestion is not either-or. Anchor the science where it needs anchoring, and put the enrollment engine where the patients already are. If you want to see what the community side of that split can commit to, a synopsis to trials@stryderesearch.com gets you an answer in 48 business hours.